Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9870399 | 0.89 | ALDH1A1 (0.36) | BCHEADORA2AEPHX1SMN1; SMN2KDM4C | |
| SCHEMBL9278494 | 0.86 | HSD17B10 (0.36) | BCHEADORA2ASMN1; SMN2KDM4CHSD17B10 | |
| SCHEMBL19303889 | 0.86 | BCHE (0.33) | BCHEADORA2ASMN1; SMN2KDM4CHSD17B10 | |
| SCHEMBL21706216 | 0.85 | SIGMAR1 (0.41) | ADORA2AEPHX1KDM4CDRD2DRD3 | |
| SCHEMBL8070563 | 0.85 | MEN1 (0.38) | BCHEADORA2AEPHX1KDM4CDRD2 | |
| SCHEMBL14679316 | 0.85 | EGLN1 (0.40) | KDM4C | |
| SCHEMBL2733557 | 0.84 | NPC1 (0.44) | BCHEEPHX1SMN1; SMN2KDM4CCACNA1H | |
| SCHEMBL14011283 | 0.83 | EPHX1 (0.48) | EPHX1HSD17B10 | |
| SCHEMBL11148743 | 0.83 | FAAH (0.37) | BCHEADORA2AEPHX1KDM4CDRD2 | |
| SCHEMBL5540331 | 0.82 | PRMT1 (0.47) | KDM4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-1279667-B1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | MITSUI CHEMICALS INC (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-6861534-B2 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2005-03-01 | — | — | US | disclosed |
| EP-1279667-A1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2003-01-29 | — | — | EP | disclosed |
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | BCHE 2944/4885ADORA2A 4610/4885EPHX1 2553/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | BCHE 2944/4885ADORA2A 4610/4885EPHX1 2553/4885 |
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | PIGS, DEK, B2M | BCHE 1645/4885ADORA2A 855/4885EPHX1 4090/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | BCHE 2944/4885ADORA2A 4610/4885EPHX1 2553/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | BCHE 2944/4885ADORA2A 4610/4885EPHX1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.